Thus, two mechanisms explain the risk of tuberculosis in patients treated with ICIs: (1) downregulation of the PD-1/PD-L1 pathway induces an exacerbated inflammatory response; (2) treatment of irAEs with corticosteroids and TNF- inhibitors favors the development of active tuberculosis [31,32]. This evidence concerns the gene TNF and tuberculosis.